Bionix Radiation Therapy Information
Contact top employees from
Bionix Radiation Therapy
Summary
Bionix Radiation Therapy is a private company. The company currently specializes in the Medical Devices area. The position of the President & CEO is occupied by David Hart. Its headquarters is located at Toledo, Ohio, USA. The Bionix Radiation Therapy annual revenue is estimated at < 1M. To connect with Bionix Radiation Therapy employee register on SignalHire.
Organization Website | BionixRT.com |
Social Links |  |
Phone Number | 1-800-624-6649 |
Industries | |
Headquarters Location | 5154 Enterprise Blvd, Toledo, OH, 43612 US |
Employees Size | 10-50 employees |
Specialties | Patient Positioning, External Immobilization |
DMA Code | Toledo Metropolitan Area |
Operating Status | Independent Company |
Competitors
Founded | Type | Employees | Revenue | Funding | |
|---|---|---|---|---|---|
| 1973 | Nonprofit | 1.0K - 5.0K | 1B | $4M | |
| 1974 | Privately Held | 25 - 100 | 14.7M | $10M | |
| 2005 | Public Company | 1.0K - 5.0K | 1.9B | $105.6M | |
| 2009 | Public Company | 1 - 25 | < 1M | $20M |
Employees Turnover 4 quarter 2025
Length of Employment
Employee tenure at Bionix Radiation Therapy shows a diverse range of experience levels:
22% for 5–7 years33% for 8–10 years44% have over 11 years of service at Bionix Radiation TherapyContact top employees from
Bionix Radiation Therapy
Jennifer Pearcy
Regional Account Manager
Lawrence Ellerbush
tool and die maker
FAQ
Bionix Radiation Therapy operates in the Medtech industries. More details can be found on the official website: BionixRT.com.
The headquarters of Bionix Radiation Therapy are located in Toledo, United States.
The current CEO of Bionix Radiation Therapy is David Hart
You can contact Bionix Radiation Therapy by phone at 1-800-624-6649.
Bionix Radiation Therapy currently employs 10-50 people.
Bionix Radiation Therapy's revenue is approximately < 1M.
Well-known competitors of Bionix Radiation Therapy include USA Health, HIGH TIMES, Ubiquiti Inc. and Vicore Pharma AB.
